Post by Alira Health

Nuclear medicine today is propelled by scientific breakthroughs and growing investment as companies perceive the potential value of these cutting-edge therapies to patients managing cancers and other diseases. But the future of this promising sector hinges on the industry’s ability to deliver these therapies consistently and at scale. The white paper below examines the stages of the radiopharmaceutical supply chain and how political tensions, cross-border dependencies, and capacity constraints impact each stage. It also outlines a five-part strategy framework for stakeholders to strengthen supply chain resilience, optimize manufacturing networks, and navigate the complex reimbursement landscape.